OCTAVE: A phase I study of enadenotucirev, an oncolytic group B adenovirus, in combination with weekly paclitaxel in platinum-resistant epithelial ovarian cancer

dc.contributor.author	McNeish, IA
dc.contributor.author	Moreno, V
dc.contributor.author	Jayson, Gordon C
dc.contributor.author	Roxburgh, P
dc.contributor.author	Ginesta, MPB
dc.contributor.author	Garcia-Donas, J
dc.contributor.author	Torres, AA
dc.contributor.author	Michael, A
dc.contributor.author	Brown, R
dc.contributor.author	Krige, D
dc.contributor.author	Bendall, J
dc.contributor.author	Di Genova, G
dc.contributor.author	McElwaine-Johnn, H
dc.date.accessioned	2019-12-09T17:23:30Z
dc.date.available	2019-12-09T17:23:30Z
dc.date.issued	2019	en
dc.identifier.citation	McNeish IA, Moreno V, Jayson G, Roxburgh P, Ginesta MPB, Garcia-Donas J, et al. 1031P OCTAVE: A phase I study of enadenotucirev, an oncolytic group B adenovirus, in combination with weekly paclitaxel in platinum-resistant epithelial ovarian cancer. Annals of Oncology. 2019;30(Supplement_5):421.	en
dc.identifier.doi	10.1093/annonc/mdz250.039	en
dc.identifier.uri	http://hdl.handle.net/10541/622589
dc.language.iso	en	en
dc.relation.url	https://dx.doi.org/10.1093/annonc/mdz250.039	en
dc.title	OCTAVE: A phase I study of enadenotucirev, an oncolytic group B adenovirus, in combination with weekly paclitaxel in platinum-resistant epithelial ovarian cancer	en
dc.type	Meetings and Proceedings	en
dc.contributor.department	Department of Surgery and Cancer, Imperial College London, London	en
dc.identifier.journal	Annals of Oncology	en
refterms.dateFOA	2020-01-21T20:08:26Z

Name:

mdz250.039.pdf

Size:

70.14Kb

Format:

PDF

Description:

From UNPAYWALL. Conference abstract